Would you consider using nab-paclitaxel/gemcitabine/cisplatin in first line setting for metastatic pancreatic adenocarcinoma?

The data recently published in JAMA Oncology are certainly intriguing and merit further study. However, this remains a very small trial of only 25-patients with uncertainty as to its real-world performance or demonstration of efficacy in a randomized trial. It also is uncertain what implications pla...